Renforth Resources Inc., a Canadian junior gold exploration company, will participate in the 3rd Annual ArcStone Kingswood Growth Summit in Toronto on September 16, 2026. Nicole Brewster, the company's President and CEO, will engage in one-on-one meetings with investors and capital market professionals. The summit gathers growth issuers and investors for presentations, networking, and discussions on industry developments. This event offers Renforth an opportunity to showcase its projects, including the Parbec gold deposit and Victoria polymetallic deposit, to potential investors and partners.
Renforth Resources is attending the ArcStone Kingswood Growth Summit 2026 in Toronto. For readers following Basic Materials, here is Pluang's market snapshot as of Sep 15, 2026 21:43 WIB: of 32 priced US Basic Materials stocks, 10 rose and 22 fell. Notable prices include SLI at USD 2.04 (-2.39%), EXK at USD 9.51 (-2.16%), and LYB at USD 64.10 (+2.14%).
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
